Shandong Xinhua Pharmaceutical (00719.HK) +0.020 (+0.337%) Short selling $95.40K; Ratio 6.258% announced that it has received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration, approving the change of holder for the artificial bezoar metronidazole capsules from Zhongsheng Pharmaceutical to Xinhua Pharmaceutical.In September 2023, Xinhua Pharmaceutical and Zhongsheng Pharmaceutical signed a contract for the transfer of production technology and holder rights. Zhongsheng Pharmaceutical will transfer all MAH rights, including but not limited to the formulation production license and commercialization rights of the artificial bezoar metronidazole capsules, such as product production, sales, and marketing, to Xinhua Pharmaceutical in a one-time transfer. Xinhua Pharmaceutical will pay the related transfer fees to Zhongsheng Pharmaceutical in stages according to the contract terms. (ss/a)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-05 16:25.)
AASTOCKS Financial News